Cowen Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cowen Inc’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,100	Closed	-$1.24K	–	519
2018 Q2	$1.24K	Buy	+13,100	New	+$1.15M	0.05%	189

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cowen Inc's BMRN Position: Q3 2018 in Review

Cowen Inc sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 1,000 shares — an estimated $94 sold.

Cowen Inc first reported a position in BMRN in Q2 2018 and held it in 1 quarter. The position peaked at $94 in Q2 2018. 460 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

Cowen Inc reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Cowen Inc sold 1,000 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $94.
Cowen Inc first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Cowen Inc's BioMarin Pharmaceuticals position peaked at $94 in Q2 2018.
460 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Cowen Inc's 13F filing for Q3 2018, filed 13 Nov 2018.